Diagnosing Light Chain Amyloidosis on Temporal Artery Biopsies for Suspected Giant Cell Arteritis by Ghinai, RAM et al.
1 
 
Diagnosing light chain (AL) amyloidosis on temporal artery biopsies for suspected giant cell 
arteritis 
 
Running title: Light chain (AL) amyloid on temporal artery biopsies 
 
Keywords: amyloidosis; diagnosis; histopathology 
 
1. Ghinai, Rosanna; Haematology, Severn Deanery, UK 
2. Mahmood, Shameem; National Amyloidosis Centre, University College London, UK 
3. Mukonoweshuro, Pinias; Histopathology, Royal United Hospital Bath, UK 
4. Webber, Sally; Ophthalmology, Royal United Hospital Bath, UK 
5. Wechalekar, Ashutosh; National Amyloidosis Centre, University College London, UK 
6. Moore, Sally; Haematology, Royal United Hospital Bath, UK 
 
We acknowledge Janet Gilbertson (National Amyloidosis Centre, University College London, 
UK) for her assistance in providing further histological images of the cases presented. 
 
Corresponding author: Dr Rosanna Ghinai (BSc, MBChB, MRCP, DTMH, MSc) 
   Royal United Hospital Bath 
Combe Park, Bath 
BA1 3NG, UK 
   rag@doctors.org.uk 
   07522 050 464 
 
There are no conflicts of interest to declare and this work has not been externally funded 
2 
 
 
Abstract 
Although still rarely diagnosed, light chain (AL) amyloidosis is the most common form 
of systemic amyloidosis. It is characterized by misfolded monoclonal immunoglobulin light 
chain fragments that accumulate extracellularly as amyloid fibrils, with consequent organ 
dysfunction. We report two such cases where initial symptoms and signs were identical to, and 
mistaken for, those of giant cell arteritis (GCA), associated with polymyalgia rheumatica (PMR). 
Neither patient responded to high dose corticosteroids; instead, their temporal artery biopsies 
revealed amyloid deposits and other investigations confirmed a diagnosis of systemic AL 
amyloidosis. Review of the literature reveals similar cases of diagnostic confusion spanning 75 
years. We have summarized the findings and learning points from cases reported in the last 30 
years, and highlight the need for increased awareness and investigation of this under-recognized 
syndrome. 
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 Light chain (AL) amyloidosis typically presents with renal, cardiac, hepatic and 
peripheral or autonomic nervous system impairment. However, recent guidelines acknowledge 
marked clinical heterogeneity. AL amyloidosis with symptoms mimicking giant cell arteritis 
(GCA) or myalgia and fatigue simulating polymyalgia rheumatic (PMR), is not a new 
phenomenon but it is unusual. We present two cases of AL amyloidosis masquerading as giant 
cell arteritis, and review the literature since 1986 (1).  We draw attention to the similarities and 
distinguishing features of AL amyloidosis versus GCA. 
Case Reports 
Patient 1 
 A 67-year-old man with Waldenstrom macroglobulinaemia experienced myalgia weight 
loss, fatigue, jaw claudication and sudden visual loss in the left eye. Visual acuity in the left eye 
was 20/80, with a left relative afferent pupil defect (RAPD) and left optic disc pallor with 
blurring of the nasal margin. His C-reactive protein (CRP) was 39 mg/L (normal: < 5 mg/L) and 
platelets were 520,000/ microlitre (normal: 150,000 - 400,000/ microliter). Temporal artery 
biopsy was not performed but the patient received Prednisolone (1mg/kg) for a presumed 
diagnosis of arteritic anterior ischemic optic neuropathy. With this treatment, there was minimal 
improvement in his vision and his other symptoms persisted. 
 Because of severe myalgia, the patient underwent magnetic resonance imagine (MRI) of 
the quadriceps muscles. The findings were suggestive of myositis, and a muscle biopsy stained 
positive with Congo red (Fig 1A) and showed apple green birefringence under polarized light 
(Fig 1B), diagnostic of the presence of amyloid. The patient was referred to the National 
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Amyloidosis Center (NAC), where immunostaining of the muscle biopsy was positive for 
antibodies to kappa light chains (Fig 1C) and negative for antibodies to lambda light chains (Fig 
1D). Transthyretin deposition was excluded and kappa light chain type amyloid was confirmed 
by liquid chromatography mass spectrometry (LC-MS) and proteomic analysis. Further 
investigations showed:  no visceral amyloid deposits by 123I serum amyloid P component (SAP) 
scintigraphy; no cardiac involvement by echocardiography; and no evidence of amyloid on bone 
marrow or renal biopsies. 
 Eight months after left visual loss, the patient experienced sudden loss of vision in his 
right eye. Visual acuity was 20/200, right eye, and light perception, left eye, with a left RAPD. 
The right optic disc was pale and swollen and left disc was atrophic. CRP was 93 mg/L and 
platelet count was 180,000/ microliter. A right temporal artery biopsy was performed, showing 
eosinophilic infiltrates and focal inflammation within the media (Fig 2A), confirmed as amyloid 
with Congo red staining (Fig 2B), and no evidence of giant cell arteritis. The patient developed 
diarrhea, breathlessness, hypotension and edema. He commenced Rituximab, Bortezomib, and 
Dexamethasone, but died during his first treatment cycle. 
Patient 2 
 A 69-year-old man with a 35 year history of IgD kappa monoclonal gammopathy of 
undetermined significance (MGUS) with a stable paraprotein of 5g/L and ankylosing spondylitis, 
was referred to the rheumatology service for symptoms of myalgia, fatigue, global weakness, jaw 
claudication and scalp tenderness. Recently, he had been investigated for paraesthesias and 
diagnosed with carpal tunnel syndrome and axonal neuropathy. His CRP was 33 mg/L and 
platelet count was 486,000/microliter. Duplex ultrasonography of the temporal arteries revealed 
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arterial wall edema (hyperechoic “halo”) consistent with arteritis, normal velocities and no 
stenosis (2). He was diagnosed with GCA and PMR and treated with high dose steroids without 
symptomatic relief. Therefore, he underwent temporal artery biopsy which stained positively 
with Congo red (Fig 3A), showing apple green birefringence in polarized light (Fig 3B) and 
orange fluorescence under tetramethylrhodamine isothiocyanate (TRITC) filter (Fig 3C). 
Immunostaining was positive for antibodies to kappa light chains (Fig 3D) and negative for 
antibodies to lambda light chains (Fig 3E).  No transthyretin was detected. Giant cells were 
present as a foreign body reaction to amyloid deposits, but not centered upon the internal elastic 
lamina as in giant cell arteritis. Cardiac involvement was detected on MRI. The patient had lytic 
bone lesions, renal impairment, hypercalcemia and anemia. His bone marrow confirmed 
myeloma, with up to 90% plasma cells and evidence of amyloid with Congo red staining. At the 
National Amyloidosis Center, a fat biopsy was positive for amyloid, and 123I serum amyloid P 
component scintigraphy did not reveal visceral amyloid deposits. 
Discussion 
 Reviewing the literature of AL amyloidosis mimicking GCA yielded 15 reports in the last 
30 years (3-16). These are combined with our two patients and summarized in Table 1. These 
cases illustrate aspects of diagnostic confusion between GCA/ PMR and AL amyloidosis, 
including clinical findings, investigation results and response to steroid treatment. 
 A patient with AL amyloidosis involving the temporal artery is likely to fulfill the 
classification criteria for GCA on a clinical basis in the absence of histology (2). AL amyloidosis 
may mimic GCA with jaw claudication [(9% of cases (1)] and neuro-ophthalmologic 
involvement including anterior ischemic optic neuropathy (Table 2). In addition, non-specific 
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symptoms such as myalgia and fatigue may overlap with those of PMR (17). Patients with a 
known plasma cell dyscrasia or hematological malignancy and features of ‘PMR’ should be 
investigated for AL amyloidosis. This includes histological diagnosis from an affected organ, 
measurement of serum free light chains, and immunofixation of blood and urine (18). 
 In AL amyloidosis, amyloid is thought to occlude the arterioles feeding the masseter, 
causing jaw claudication in a similar manner to lower limb claudication in predominantly 
vascular amyloidosis (M Gertz, personal communication, April 2016). Estrada et al (9) reported 
a case of “co-existent GCA and AL amyloidosis”; but giant cells and macrophages were 
engulfing amyloid depositis. It may be misleading to label this as a case of GCA, preferable 
instead to refer to it as a secondary arteritis. Because amyloid also may cause arterial narrowing 
leading to ischemia, Neri et al (14) speculated that ischemic optic neuropathy in AL amyloidosis 
could be due to reduced adaptability to fluctuations in blood pressure (nocturnal hypotension). 
 Other areas of diagnostic confusion include laboratory findings, imaging and response to 
steroids. Raised inflammatory markers (ESR or CRP), thrombocytosis and a normocytic anemia 
may all be seen in GCA, PMR and AL amyloidosis (12). Dhodapkar and colleagues (19) 
reported that 60% of their cohort of 93 patients with symptomatic amyloidosis had at least 
someinitial symptomatic response to high dose steroids. This is another potential factor in 
delayed diagnosis of AL amyloidosis. Without acknowledging the possibility of an alternative 
diagnosis, current guidelines for GCA state that patients with negative biopsies should be 
managed as GCA if there are typical clinical and laboratory features, ultrasound findings and 
steroid response (20). Several patients in this case series displayed all of these, leading to 
delayed recognition and treatment of AL amyloidosis. In two cases, amyloid was only identified 
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on re-staining original temporal artery biopsies with Congo red many months later, showing that 
deposits are easily missed on H&E staining alone. 
 It is essential that an experienced pathologist is aware of alternate diagnoses when 
examining temporal artery biopsy specimens as “false negative and false positive diagnoses on 
the basis of histology are not infrequent” (18). Our paper illustrates the potential perils of 
overlooking histology, especially in our first patient. Delays in diagnosis and management of AL 
amyloidosis are a major factor in morbidity and mortality; heightened suspicion of this diagnosis 
by clinicians is required.  
In summary, in suspected GCA (even with neuro-ophthalmic involvement), prompt 
temporal artery biopsy and Congo red staining is crucial. If GCA is not evident, investigation for 
an underlying plasma cell dyscrasia must follow; with serum free light chains, immunofixation 
of blood and urine, and muscle biopsy if features of PMR and known plasma cell dyscrasia. 
Atypical response to steroids should trigger rapid assessment for AL amyloidosis, with a dose 
review to avoid unnecessary toxicity. 
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Figure Legends 
Figure 1.  Patient 1. Muscle biopsy stains positively with Congo red (A), and demonstrates  
  apple green birefringence under polarized light (B). There is positive   
  immunostaining for antibodies to kappa light chains (C) but negative for   
  antibodies to lamda light chains (D). 
Figure 2. Patient 1. Temporal artery biopsy. A. There are amyloid deposits (dark pink  
  color) in media of vessel walls (hematoxylin & eosin, x 5). B. More extensive  
  deposition of amyloid is seen with Congo red stain (x 5). 
Figure 3. Patient 2. Temporal artery biopsy. There are amyloid deposits in the vessel wall  
  detected with Congo red stain. B. This is confirmed as amyloid with appearances  
  of apple green birefringence under polarized light. C. The Congo red stained  
  amyloid fluoresces under tetramethylrhodamine isothiocyanate (TRITC) filter.  
  The biopsy specimen stains positively for antibodies to kappa light chains (D) but  
  not for antibodies to lamda light chains (E).  
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